The results indicate that the effective dose to reduce tumor volume, which defines the therapeutic threshold, for the control groups is above 107, whereas for the anti-VEGF groups is 2 × 106 CAR-T cells (/cm3 of mouse vascular volume), 5 times lower. The gene discussed is VEGFA; the disease is neoplasm.